公开(公告)号：US20230313308A1

公开(公告)日：2023-10-05

申请号：US17713143

申请日：2022-04-04

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  Singapore Health Services Pte Ltd ,  National University Hospital (Singapore) Pte Ltd ,  Tan Tock Seng Hospital Pte Ltd ,  MiRXES Lab Pte. Ltd.

Inventor： Siew Gek Lee-Lim ,  Ruiyang Zou ,  Lihan Zhou ,  He Cheng ,  Bo Anders Mikael Hartman ,  Heng-Phon Too

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/178 ,  C12Q2600/158 ,  C12Q2600/118

Abstract: This technology relates to a method of treating breast cancer in a subject and a method of determining whether a breast lesion in a subject is malignant or benign using miRNA panels.

公开(公告)号：US20240352530A1

公开(公告)日：2024-10-24

申请号：US18293816

申请日：2022-08-02

Applicant: National University of Singapore ,  Singapore Health Services Pte. Ltd. ,  MiRXES Lab Pte. Ltd. ,  National University Hospital (Singapore) Pte Ltd

Inventor： Mikael Hartman BO ANDERS ,  Heng-Phon TOO ,  Siew Gek Ann LEE-LIM ,  Ruiyang ZOU ,  Lihan ZHOU ,  He CHENG

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/178 ,  G01N2800/50

Abstract: Disclosed herein is a method for determining whether a subject is suffering from, or is at risk of developing breast cancer, wherein the method comprises detecting differential expression levels of at least two or more miRNA markers from a biological sample. Also disclosed herein is a method of determining whether a subject is suffering from, or is at risk of developing, breast cancer based on miRNA expression.

公开(公告)号：US20220186320A1

公开(公告)日：2022-06-16

申请号：US17594805

申请日：2020-04-14

Applicant: MiRXES Lab Pte. Ltd.

Inventor： Ruiyang Zou

IPC: C12Q1/6886

Abstract: The present invention relates to the field of molecular biology. Disclosed are a miRNA marker combination and a kit for diagnosing gastric cancer. The miRNA marker combination for diagnosing gastric cancer includes at least four markers selected from: hsa-miR-29c-3p, hsa-miR-424-5p, hsa-miR-103a-3p, hsa-miR-93-5p, hsa-miR-181a-5p, hsa-miR-21-5p, hsa-miR-140-5p, hsa-miR-30e-5p, hsa-miR-142-5p, hsa-miR-126-3p, hsa-miR-183-5p and hsa-miR-340-5p. The marker combination for diagnosing gastric cancer can be used to distinguish blood serum of a patient with gastric cancer from that of a Healthy human. The diagnostic kit of the present invention can diagnosis gastric cancers easily, effectively and non-invasively.

公开(公告)号：US20220081722A1

公开(公告)日：2022-03-17

申请号：US17415881

申请日：2019-12-17

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  MIRXES LAB PTE LTD

Inventor： Heng Phon Too ,  Ka Yan Chung ,  Jia Min Quek Yang Zou ,  Rui Yang Zou

IPC: C12Q1/6886 ,  C12N15/113 ,  A61P35/00

Abstract: We describe a method of diagnosing a gastric cancer. The method may include detecting the expression level of an miRNA in a sample of or from an individual. The expression level of the miRNA may be detected in an extracellular vesicle (EV) from the sample. The miRNA may be selected from the group consisting of: hsa-miR-484, hsa-miR-186-5p, hsa-miR-142-5p, hsa-miR-320d, hsa-miR-320a, hsa-miR-320b and hsa-miR-17-5p. The method may be such that an altered expression level of the miRNA as compared to the expression level of the miRNA in an EV in or of an individual known not to be suffering from gastric cancer indicates that the individual is suffering, or is likely to be suffering, from gastric cancer.